期刊文献+

造血干细胞移植中氟康唑与伊曲康唑短疗程预防真菌感染的观察 被引量:1

Effect of short course treatment of fluconazole and itraconazole in preventing invasive fungal infection in patients after allogeneic hematopoietic stem cell transplantation
原文传递
导出
摘要 目的比较异基因造血干细胞移植患者应用氟康唑和伊曲康唑预防侵袭性真菌感染的疗效及安全性。方法回顾分析192例异基因造血干细胞移植患者予短疗程(30d)氟康唑或伊曲康唑行真菌一级预防,其中应用氟康唑134例,伊曲康唑58例,比较两组患者侵袭性真菌感染的发生和转归情况。结果氟康唑组和伊曲康唑组移植30、60、90、180d侵袭性真菌感染的发生率分别为9.0%和5.2%、16.5%和6.9%、17.2%和8.7%、22.0%和16.4%,差异均无统计学意义(P值分别为0.370、0.081、0.128、0.309),但移植后60d时P值明显较小。真菌感染发生部位均以肺部为主。患者均能很好耐受两药,但伊曲康唑副反应较大(19.0%vs2.2%,P=0.000)。结论短疗程伊曲康唑与氟康唑预防异基因造血干细胞移植后侵袭性真菌感染在移植60d时伊曲康唑较氟康唑显示了一定的优势。 Objective To compare the effeciency of fluconazole and itraconazole in preventing invasive fungal infection in patients after allogeneic hematopoietic stem cell transplantation. Methods 192 cases were divided into fluconazole group consisted of 134 patients and itraconazole group consisted of 58 patients.The occurrence and prognosis of invasive fungal infection between the two groups were compared. Results The incidence rates of invasive fungal infection in fluconazole and itraconazole group were respectively 9.0% and 5.2% ,16.5% and 6.9% ,17.2% and 8.7% ,22% and 16.4% at 30days, 60days, 90days and 180days after transplantation (P=0.370,0.081,0.128 and 0.309, respectively).There are more side effects in patients ~iven itraconazole. Conclusion Itraconazole annear to manife^st certain ~un^rinrltv At 60 claw After/rAn^r~l^nt^tlnn
出处 《热带医学杂志》 CAS 2011年第6期633-636,共4页 Journal of Tropical Medicine
关键词 侵袭性真菌感染 预防治疗 异基因造血干细胞移植 invasive fungal infection prevention allogeneic hematopoietic stem cell transplantation
  • 相关文献

参考文献10

  • 1赵孟霞,孙竞,范志平,刘启发,毛玉景,江千里,韦祁,赵婕.氟康唑与伊曲康唑预防造血干细胞移植真菌感染的效果[J].中国热带医学,2010,10(9):1064-1066. 被引量:3
  • 2血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(修订版)[J].中华内科杂志,2007,46(7):607-610. 被引量:250
  • 3Garcia-Vidal C, Upton A, Kirby KA, et al.Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time aftertransplantation [ J ].Clin Infect Dis, 2008,47 ( 8 ) : 1041-1050.
  • 4Sheehan DJ, Hitchcock CA, Sibley CM.Current and emerging azole antifungal agents [ J ].Clin Microbiol Rev, 1999,12 ( 1 ) : 40-79.
  • 5De Beule K.Itraconazole: pharmacology,clinical experience and future development [ J ] .Int J Antimicrob Agents, 1996,6 ( 3 ) : 175- 181.
  • 6Bow EJ.Invasive fungal infection in haematopoietic stem celt transplant recipients: epidemiology from the transplant physician's viewpoint [ J ] Mycopathologia, 2009,168 (6) : 283-297.
  • 7Winston DJ, Maziarz RT, Chandrasekar PH,et al.Intravenous and oral itraconazole versus intravenous and oral fluconazole for long- term antifungal prophylaxis in allogeneic hematopoietic stem-celltransplant recipients.A multicenter, randomized trial [ J ].Ann Intern Med,2003,138(9) :705-713.
  • 8Marr KA,Crippa F,Leisenring W,et al.Itraconazole fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants [J]. Blood, 2004, 103 (4) : 1527 -1533.
  • 9Mart KA,Carter RA,Boeckh M,et al.Invasive aspergillosis in allogeneic stem cell transplant recipients:changes in epidemiology and risk factors [ J ].Blood, 2002,100 ( 13 ) : 4358 -4366.
  • 10Martin T,Sharma M,Damon L,et al.Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation [J].Transpl Infect Dis ,2010,12( 1 ) :45-50.

二级参考文献13

  • 1黄晓军.血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(草案)[J].中华内科杂志,2005,44(7):554-556. 被引量:423
  • 2王景枝,刘代红,许兰平,陈欢,刘开彦,黄晓军.伊曲康唑在异基因造血干细胞移植患者真菌感染中的应用[J].中华内科杂志,2007,46(1):29-31. 被引量:7
  • 3血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(修订版)[J].中华内科杂志,2007,46(7):607-610. 被引量:250
  • 4Garcia-Vidal C, Upton A, Kirby K A, et al . Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation [J] . Clinical Infectious Diseases, 2008,47(8 ) : 1041-1050.
  • 5Upton A,Kirby KA,Carpenter P,et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality [J]. Clinical Infectious Diseases,2007,44 (4) :531-540.
  • 6Winston D J, Maziarz RT, Chandrasekar PH, et al . Longterm antifungal prophylaxis in allogeneic bone marrow transplant patients: a multicenter, randomized trial of intravenous/oral it -raconazole versus intravenous/ oral fluconazole[J]. Annals of Internal Medicine, 2003,138(6) : 705.
  • 7Mart KA, Crippa F, Leisenring W, et al. Itraconazole versus flueonazole for prevent of fungal infections in patient sreceiving allogeneic stem cell transplants [J]P. Blood ,2004,103 (4) : 1527.
  • 8Glasmacher A,Prentice AEvidence based review of antifungal prophylaxis in neutropenicpatient swith haematological malignancies [J] .JAntimicrob Chemother, 2005,56 ( 1 ) : 23.
  • 9Morgenstern GR,Prentice AG,Prentice HG,et al . A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group [J] . British Journal of Haematology, 1999,105(4) :901-911.
  • 10Winston, DJ ; Maziarz, RT; Chandrasekar, PH; et al . Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter,randomized trial [J] . Annals of Internal Medicine,2003,138(9) : 705-713.

共引文献251

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部